Opyl Limited Streamlines with Trial Screen Transition

Opyl Ltd. (AU:OPL) has released an update.

Opyl Limited has announced that Opin has been successfully rebranded as Trial Screen following its acquisition by Dr. Hugo Stephenson, who plans to invest $1.2 million into the business. Opyl will retain a 20% stake in Trial Screen, allowing it to focus on growing its TrialKey product and improving its financial position to target high-growth areas in clinical trials and medical research.

For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.